Avalo Therapeutics (AVTX) FCF Margin (2016 - 2025)
Avalo Therapeutics posted quarterly FCF Margin of 24216.95% for Q4 2025, down 1638153.0% year-on-year from N/an in Q4 2024, and down 209.07% on a QoQ basis from 7835.42% in Q4 2024.
Avalo Therapeutics (AVTX) has 10 years of FCF Margin data on file, last reported at 24216.95% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin fell 1638153.0% year-over-year to 24216.95%; the trailing twelve-month figure through Dec 2025 stood at 10300.0% (up 82381.0% YoY), and the FY2025 full-year result was 87288.14%, down 7616433.0% from the prior year.
- FCF Margin for Q4 2025 stood at 24216.95%, down from 7835.42% in the prior quarter.
- Across five years, FCF Margin topped out at 38.04% in Q3 2022 and bottomed at 24216.95% in Q4 2025.
- The 5-year median for FCF Margin is 1714.77% (2023), against an average of 4024.96%.
- The widest annual swing landed in 2022, when FCF Margin surged 738366 bps; it then sank 1638153 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 7812.79% in 2021, then surged by 95 bps to 429.13% in 2022, then declined by 13 bps to 484.41% in 2023, then plunged by 1518 bps to 7835.42% in 2024, then plunged by 209 bps to 24216.95% in 2025.
- The last three FCF Margin figures came in at 24216.95% (Q4 2025), 7835.42% (Q4 2024), and 4629.32% (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24,216.95% |
| Dec 31, 2024 | -7,835.42% |
| Sep 30, 2024 | -4,629.32% |
| Dec 31, 2023 | -484.41% |
| Sep 30, 2023 | -2,896.61% |
| Jun 30, 2023 | -1,714.77% |
| Mar 31, 2023 | -2,149.47% |
| Dec 31, 2022 | -429.13% |
| Sep 30, 2022 | 38.04% |
| Jun 30, 2022 | -1,212.58% |
| Mar 31, 2022 | -1,369.74% |
| Dec 31, 2021 | -7,812.79% |
| Sep 30, 2021 | -1,212.67% |
| Jun 30, 2021 | -571.89% |
| Mar 31, 2021 | -3,876.74% |
| Dec 31, 2020 | -960.25% |
| Sep 30, 2020 | -1,074.08% |
| Jun 30, 2020 | -639.39% |
| Mar 31, 2020 | -208.39% |
| Dec 31, 2019 | -289.32% |
| Sep 30, 2019 | -346.18% |
| Jun 30, 2019 | -489.12% |
| Mar 31, 2019 | -127.60% |
| Dec 31, 2018 | 39.19% |
| Sep 30, 2018 | -14.17% |
| Jun 30, 2018 | -7.11% |
| Mar 31, 2018 | -6.68% |
| Dec 31, 2017 | -134.19% |
| Sep 30, 2017 | 76.35% |
| Jun 30, 2017 | -1,114.74% |
| Mar 31, 2017 | -582.57% |
| Dec 31, 2016 | -2,045.16% |
| Sep 30, 2016 | -1,070.13% |
| Jun 30, 2016 | -573.40% |